Maraviroc for previously treated patients with R5 HIV-1 infection Academic Article uri icon

Overview

MeSH Major

  • CCR5 Receptor Antagonists
  • Cyclohexanes
  • HIV Fusion Inhibitors
  • HIV Infections
  • HIV-1
  • Triazoles

abstract

  • Maraviroc, as compared with placebo, resulted in significantly greater suppression of HIV-1 and greater increases in CD4 cell counts at 48 weeks in previously treated patients with R5 HIV-1 who were receiving OBT. (ClinicalTrials.gov numbers, NCT00098306 and NCT00098722.)

publication date

  • October 2, 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3078519

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa0803152

PubMed ID

  • 18832244

Additional Document Info

start page

  • 1429

end page

  • 41

volume

  • 359

number

  • 14